Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Operating Cash Flow
Cash generated by the company's core business operations during the period.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow of -$16.79M in Q2 FY2026
Q2 FY2026 operating cash flow was -$16.79M.
Context
- Operating cash flow amounted to 4385.1% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (59.2M) USD
- Year-over-year change
- -69.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (59.2M) | -69.0% |
| FY2024 | 2024-12-31 | (35.04M) | — |
Operating Cash Flow vs competitors
How ATTO compares with its peers on the latest reported figures
- ATTO's FY2025 operating cash flow of $59.2M is the 6th largest of the 10 companies compared; the peer median is $72.68M.
- Its year-over-year change of +69.0% is the 5th highest of 9, against a peer median of +82.2%.
- Operating cash flow amounts to 4385.1% of revenue for ATTO, versus a peer median of 712.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $351.4M | +1.8% | +50.8% | 4749.9% |
| LTM Mar 2026 | $224.15M | +60.4% | +51.9% | — | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $123.64M | +46.4% | +100.7% | — |
EVMNEvommune, Inc. | LTM Mar 2026 | $80.05M | — | — | 800.5% |
ZURAZura Bio Limited | LTM Mar 2026 | $72.68M | +112.8% | +277.8% | — |
| FY2025 | $59.2M | +69.0% | — | 4385.1% | |
| LTM Mar 2026 | $52.21M | +323.8% | -11.3% | 623.9% | |
| FY2025 | $51.21M | +116.9% | -19.8% | 80009.4% | |
| LTM Mar 2026 | $27.4M | -58.3% | +45.2% | 51.0% | |
| LTM Mar 2026 | $4.48M | +104.1% | — | 1.9% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ATTO) | $72.68M | +82.2% | +50.8% | 712.2% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (45.05M) | (60.9M) |
| Depreciation & Amortization | 313K | 804K |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 1.54M | 276K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 1.72M | 180K |
| Other Working Capital | (181K) | 96K |
| Other Non-Cash Items | 8.16M | 619K |
| Operating Cash Flow | (35.04M) | (59.2M) |
| Capital Expenditures | (1.77M) | (2.31M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (46.03M) | (221.89M) |
| Sales of Investments | 8M | 150.75M |
| Other Investing Activities | 0 | 0 |
| Investing Cash Flow | (39.8M) | (73.46M) |
| Debt Repayment | (171K) | 0 |
| Common Stock Issued | 82.92M | 142.01M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 82.75M | 142.01M |
| Effect of Forex Changes | 22.73M | 203K |
| Net Change in Cash | 30.63M | 9.56M |
| Free Cash Flow | (36.81M) | (61.51M) |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.